SCHEMBL16132004

SCHEMBL16132004

Cc1ccc(CN2CCC2)nc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 7/20 0.49
KCNH2 Q12809 2/20 0.41
SCN5A Q14524 1/20 0.41
SCN9A Q15858 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 1/20 0.40
RCE1 Q9Y256 1/20 0.40
CCR1 P32246 1/20 0.39
CCR5 P51681 1/20 0.39
CCR8 P51685 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
PDE10A Q9Y233 1/20 0.38
CXCR4 P61073 1/20 0.38
LMNA P02545 1/20 0.38
POLB P06746 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12894384 0.96 HRH3 (0.53) HRH3KCNH2SCN5ASCN9ACYP1A2
SCHEMBL12064 0.95 HRH3 (0.55) HRH3KCNH2SCN5ASCN9ACYP1A2
SCHEMBL17409830 0.86 HRH3 (0.55) HRH3CYP1A2ALDH1A1KDM4ECXCR4
SCHEMBL7617880 0.86 ALDH1A1 (0.56) HRH3KCNH2SCN5ASCN9AALDH1A1
SCHEMBL12513 0.86 LTA4H (0.45) HRH3KCNH2SCN5ASCN9AALDH1A1
SCHEMBL20160684 0.84 CXCR4 (0.49) HRH3KCNH2SCN5ASCN9ACYP2D6
SCHEMBL12310670 0.84 HRH3 (0.53) HRH3CYP1A2ALDH1A1CXCR4NPC1
SCHEMBL20071132 0.84 KCNH2 (0.39) HRH3KCNH2SCN5ASCN9AALDH1A1
SCHEMBL17828175 0.83 ALDH1A1 (0.48) HRH3KCNH2SCN5ASCN9ACYP2D6
SCHEMBL12426 0.83 KCNH2 (0.46) HRH3KCNH2SCN5ASCN9APDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140288044-A1 COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) 2014-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140288044-A1 COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS CSNK1G1, PRKCE, PHKG1 HRH3 4523/4885KCNH2 3940/4885SCN5A 2804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.